PMID- 29705017
OWN - NLM
STAT- MEDLINE
DCOM- 20190307
LR  - 20220419
IS  - 1938-0690 (Electronic)
IS  - 1525-7304 (Linking)
VI  - 19
IP  - 4
DP  - 2018 Jul
TI  - Treatment Satisfaction of Patients With Advanced Non-Small-cell Lung Cancer 
      Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study 
      (PERSONAL).
PG  - e503-e516
LID - S1525-7304(18)30045-7 [pii]
LID - 10.1016/j.cllc.2018.03.003 [doi]
AB  - INTRODUCTION: In patients with advanced non-small-cell lung cancer, the treatment 
      benefits and risks need to be constantly weighed. We explored patient-reported 
      satisfaction with therapy (SWT) and assessed its value in addition to quality of 
      life (QoL) and adverse events (AEs). PATIENTS AND METHODS: In a prospective 
      multicenter cohort study, patients with stage IIIB/IV non-small-cell lung cancer 
      received platinum-pemetrexed chemotherapy. They completed the World Health 
      Organization Quality of Life-BREF (WHOQoL-BREF) and European Organization for 
      Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC 
      QLQ-C30) before and during chemotherapy. After the last cycle, patients reported 
      on SWT, expectations of therapy, and feelings about side effects (FSE) using the 
      Cancer Therapy Satisfaction Questionnaire. The explained variance (R(2)) of QoL 
      after treatment by SWT was calculated. Using multivariable linear regression, we 
      examined the association of SWT with patient- and treatment-related variables, 
      FSE, and AEs. RESULTS: Eighty-nine patients finished 4 cycles of chemotherapy, 65 
      of whom completed the Cancer Therapy Satisfaction Questionnaire. Fifty-six 
      patients (86.2%) would probably or definitely decide to undergo the same 
      treatment again, regardless of deterioration or improvement in QoL or a high or 
      low frequency of AEs during chemotherapy. The explained variance of QoL by SWT 
      was greatest for the EORTC QLQ C-30 global health status/QoL scale (R(2) = 
      0.170). Patient age (beta = 0.43; 95% confidence interval [CI], 0.05-0.82), FSE 
      (beta = 0.17; 95% CI, 0.06-0.29), and tumor response (beta = 7.93; 95% CI (1.64 to 
      14.22)) were independently associated with SWT. CONCLUSION: SWT could provide 
      important supplementary information in addition to QoL assessments and treatment 
      toxicities. Tumor response, older age, and FSE score were associated with better 
      SWT. These insights could affect decision-making during palliative chemotherapy.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Visser, Sabine
AU  - Visser S
AD  - Department of Pulmonary Medicine, Amphia Hospital Breda, Breda, The Netherlands; 
      Department of Pulmonary Medicine, Erasmus Medical Center Cancer Institute, 
      Rotterdam, The Netherlands; Department of Epidemiology, Erasmus Medical Center 
      University Medical Center, Rotterdam, The Netherlands.
FAU - de Mol, Mark
AU  - de Mol M
AD  - Department of Pulmonary Medicine, Amphia Hospital Breda, Breda, The Netherlands; 
      Department of Pulmonary Medicine, Erasmus Medical Center Cancer Institute, 
      Rotterdam, The Netherlands.
FAU - Cheung, Kiki
AU  - Cheung K
AD  - Department of Epidemiology, Erasmus Medical Center University Medical Center, 
      Rotterdam, The Netherlands; Inspectorate of Health Care, Utrecht, The 
      Netherlands.
FAU - van Toor, Jermo J
AU  - van Toor JJ
AD  - Department of Pulmonary Medicine, Erasmus Medical Center Cancer Institute, 
      Rotterdam, The Netherlands.
FAU - van Walree, Nico C
AU  - van Walree NC
AD  - Department of Pulmonary Medicine, Amphia Hospital Breda, Breda, The Netherlands.
FAU - Stricker, Bruno H
AU  - Stricker BH
AD  - Department of Epidemiology, Erasmus Medical Center University Medical Center, 
      Rotterdam, The Netherlands; Inspectorate of Health Care, Utrecht, The 
      Netherlands. Electronic address: b.stricker@erasmusmc.nl.
FAU - Den Oudsten, Brenda L
AU  - Den Oudsten BL
AD  - Department of Medical and Clinical Psychology, Centre of Research on 
      Psychological and Somatic Disorders, Tilburg University, Tilburg, The 
      Netherlands.
FAU - Aerts, Joachim G J V
AU  - Aerts JGJV
AD  - Department of Pulmonary Medicine, Amphia Hospital Breda, Breda, The Netherlands; 
      Department of Pulmonary Medicine, Erasmus Medical Center Cancer Institute, 
      Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20180317
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Carboplatin/administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Palliative Care/methods
MH  - *Patient Satisfaction
MH  - Pemetrexed/administration & dosage/adverse effects
MH  - Prospective Studies
MH  - *Quality of Life
OTO - NOTNLM
OT  - CTSQ
OT  - NSCLC
OT  - Palliative chemotherapy
OT  - Quality of life
OT  - Satisfaction with therapy
EDAT- 2018/05/01 06:00
MHDA- 2019/03/08 06:00
CRDT- 2018/04/30 06:00
PHST- 2017/09/11 00:00 [received]
PHST- 2018/02/05 00:00 [revised]
PHST- 2018/03/10 00:00 [accepted]
PHST- 2018/05/01 06:00 [pubmed]
PHST- 2019/03/08 06:00 [medline]
PHST- 2018/04/30 06:00 [entrez]
AID - S1525-7304(18)30045-7 [pii]
AID - 10.1016/j.cllc.2018.03.003 [doi]
PST - ppublish
SO  - Clin Lung Cancer. 2018 Jul;19(4):e503-e516. doi: 10.1016/j.cllc.2018.03.003. Epub 
      2018 Mar 17.